IN THE UNITED STATES PA	ATENT AND TRADEMARK OFFICE
In re application of:) Examiner: Nichols, Christopher J.
JAN 1 4 2005 Exevin P. BAKER, et al.) Art Unit: 1647
Application Serial No. 10/017,867) Confirmation No: 6854
Filed: December 13, 2001) Attorney's Docket No. 39780-2830 P1C60
For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC) Customer No. 35489

EXPRESS MAIL LABEL NO. <u>EL 977 612 777 US</u>

ACIDS ENCODING THE SAME

DATE MAILED: JANUARY 14, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

01/24/2005 MAHMED1 00000103 081641 10017867 02 FC:1806 180.00 DA

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):										
		(1) than	a co	It is being filed ontinued prosed OR						g date and i	s other
		(2)		It is being filed	l within	3 months	s of entr	y of a nat	tional st	tage	
		(3) mer	its	It is being filed	l before	the mail	date of t	he first (Office A	action on th	e
		(4) of a		It is being filed test for continu					ce Actio	on after the	filing
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Offic action on the merits, but before the mailing date of the earlier of a final office action under §1.1 or a notice of allowance under §1.311, then:					al Office					
		a certification	n as	specified in §1	l.97(e) i	s provide	ed below	; or			
				as set forth in other papers file					losed, o	or included	with
	37 C.F.R. $\S1.97(d)$. If this statement is being filed after the mailing date of the earlier of a fin office action under $\S1.113$ or a notice of allowance under $\S1.311$, but before payment of the is fee, then:										
	A.	a certification	n as	specified in §1	l.97(e) i	s comple	ted belo	w; and			
	B.	a petition un submitted he		37 C.F.R. §1.9 ith; and	7(d) req	uesting c	onsidera	ition of t	his state	ement is	
	C.			as set forth in other papers file					nclosed	, or include	d with
\boxtimes	Fee Authorization. The Commissioner is hereby authorized to charge the above-reference of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39780-2830 P1				with this						
					Respe	ctfully su	bmitted	•			
							R				
Dated:	January	14, 2005			By:	Anna L. B) AN Barry (Re	No. 5	1.436)	_	
275 Mi Menlo Telepho	ddlefield Park, Ca one: (65			& McAULIFF 506		mu D. D		19 . 110. 3	-,		

-2-

Form PTO-1449 O INFORMATION DISCLOSURE STATEMENT JAN 1 4 2000 several sheets if necessary)				Attorney's Docket No. 39780-2830 P1C60 Application Serial No. 10/017,867							
				Applicant(s) Kevin P. BAKER, et al.							
				Filing Date: December 13, 2001	oup Art Unit: 47						
	3	NAME OF STREET		U.S. PATENT DOCUMENTS		india Data 1	•				
Pyaminer Initials	No. Date Document No.		Document No.	Name	Class	Subclass	s Filing Date (if appropriate)				
			EC	 DREIGN PATENT DOCUMENTS		Shiftman					
Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Translation				
Initials	No.						YES	NO			
					-						
	<u> </u>		 (including	OTHER DOCUMENTS g author, title, date, pertinent pages, e	tc.)						
Examiner Initials	Ref. No.	Title									
	1.	Hanna, J.S., et al., "HER-2/neu Breat Cancer Predictive Testing", Oathology Associates Medical Laboratores - (1999).									
	2.	Hyman, E., et al., "Impact of DNA Amplification on Gene Expression Patterns in Breast Cancer ^{1,2} ", <i>Cancer Research</i> – 62:6240-6245 (2002)									
	3.	Orntoft, T.F., et al., "Genome-wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-Invasive and Invasive Human Transitional Cell Carcinomas", <i>Molecular & Cellular Proteomics</i> - 1:37-45 (2002)									
4. Pollack, J.R., et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Altera Transcriptional Program of Human Breast Tumors", <i>PNAS</i> – <u>99(20)</u> :12963-12968 (2002)							on in the				
	ļ			Mark .							
			· · · · · · · · · · · · · · · · · · ·								

	<u> </u>										
											

EXAMINER:	DATE CONSIDERED:
EXAMINER: In	iltial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in
conformance a	and not considered. Include a copy of this form with next communication to applicant.
+15 '1	the state of the second company of the provided because the reference was proviously sited by or submittee

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2094704 v1